Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01399957 · ClinicalTrials.gov registry record
Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients
A clinical trial, sponsored by Mount Sinai Rehabilitation Hospital.
- Completed
- Registry status
- 52
- Enrollment target
NCT01399957: Completed study, sponsored by Mount Sinai Rehabilitation Hospital.
NCT01399957 is a clinical trial that has completed, run by Mount Sinai Rehabilitation Hospital. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01399957 has completed, sponsored by Mount Sinai Rehabilitation Hospital.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staff will not be involved in any decisions to stop or start taking the medication.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-08 |
| Est. Completion | 2015-09 |
What the finished NCT01399957 record still lists
NCT01399957 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01399957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01399957 about?
NCT01399957 is a clinical study titled "Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients". Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampridine besides an increase in walking speed. This is strictly an observational study and research staf...
What is the current status of trial NCT01399957?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2010-08. Estimated completion is 2015-09.
Who is sponsoring clinical trial NCT01399957?
This trial is sponsored by Mount Sinai Rehabilitation Hospital, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia